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β-hydroxy fatty acids are a major component of lipid A moiety of lipopolysaccaride. We aimed to investigate the role of free β-
hydroxy fatty acids on inﬂammation, as well as to evaluate their eﬀects on cytokine release from human blood cells, and whether
they exist in plasma of patients with chronic inﬂammatory diseases with/without insulin resistance. Peripheral venous blood
was incubated with β-hydroxy lauric and β-hydroxy myristic acids (each 100ng, 1μg, 10μg/mL) up to 24 hours. Cytokines were
measured from culture media and plasma. Free fatty acids and biochemical parameters were also measured from patients’ plasma.
Only β-hydroxy lauric acid signiﬁcantly stimulated interleukin-6 production at 10μg/mL compared to control (533.9 ± 218.1
versus 438.3 ± 219.6pg/mL,P<. 0 5 ) .H o w e v e r ,f r e eβ-hydroxy lauric and myristic acids were not found in patients’ plasma.
Therefore, free β-hydroxy lauric and myristic acids do not seem to have a role on sterile inﬂammation in chronic inﬂammatory
diseases associated with insulin resistance.
Copyright © 2006 A. S. Soydan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Insulin resistance (IR) occurs in a number of diseases associ-
atedwithchronicinﬂammationsuchasmetabolicsyndrome,
type 2 diabetes, atherosclerosis, cancer, rheumatoid arthri-
tis (RA), and infections, polycystic ovary syndrome (PCOS)
[1–5]. There has been a growing body of laboratory and epi-
demiological evidence that IR and type 2 diabetes mellitus
are conditions of low-grade inﬂammation and this inﬂam-
mation is now believed to play a causative role in the patho-
genesis of these disorders [6]. What causes chronic inﬂam-
mation in such diseases is not clearly understood. Cytokines
are important mediators of inﬂammation. It has been shown
that there is a relationship between cytokines, in particular,
tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1α,
IL-1β, and IR but the mechanism is not fully understood.
TNF-α may cause IR by suppressing insulin-induced tyro-
sine phosphorylation of insulin receptor and its substrate
[7, 8]. There is a correlation between IR and serum concen-
trations of TNF-α and IL-6 in cancer patients [9, 10]. In ad-
dition, plasma concentrations of TNF-α, TNF-receptor, plas-
minogen activator inhibitor-1, and IL-6 were found to be in-
creased in obese and in type 2 diabetic patients [11–14].
Lipopolysaccaride (LPS) is a part of the outer membrane
of the cell wall of Gram-negative bacteria. The lipid A moi-
ety of LPS is responsible for its toxic eﬀects like inﬂamma-
tion, fever, tissue necrosis, endotoxic shock, and activation of
the complement system [15]. Inﬂammatory and other toxic
eﬀects of LPS are mainly via cytokines such as TNF-α,I L -
1, IL-6. β-hydroxy fatty acids, especially β-hydroxy myristic
acid and β-hydroxy lauric acid, constitute an essential part of
lipid A [15].
We hypothesized that nonbacterial β-hydroxy fatty acids,
either taken by foods or produced in the body during
fatty acid metabolism, by mimicking a chronic Gram-
negative bacterial infection, may cause chronic inﬂamma-
tion by increasing cytokine release, which may result in ﬁ-
nally IR. This study consisted of two parts. In the ﬁrst
part, we investigated the eﬀects of β-hydroxymyristic acid
and β-hydroxylauric acid on cytokine release from hu-
man peripheral blood cells. In the second part of this
study, we measured anthropometric and biochemical vari-
ables and searched whether free β-hydroxymyristic acid
and free β-hydroxylauric acid exist in plasma obtained
from patients with metabolic syndrome, cancer, RA, and
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PATIENTS AND METHODS
Healthysubjectsandpatients
The Ethics Committee of the University of Cumhuriyet ap-
proved the present study, and all participants gave written
informed consent. Peripheral venous blood samples from
healthy volunteer male subjects (n = 10) were used for in-
cubation with fatty acids. Plasma samples for fatty acid mea-
surements were obtained from patients with metabolic syn-
drome (n = 26) cancer (n = 13), RA (n = 15), and PCOS
(n = 24) according to 2003 Rotterdam criteria [16]. Con-
trol patients (n = 23) were ﬁbromyalgia since it is a nonin-
ﬂammatory rheumatic disorder. Exclusion criteria included
having disorders or using medication known to aﬀect insulin
sensitivityandsmoking.PCOSpatientshavinghormonther-
apy in the last 6 months were excluded. Individuals report-
ing a proinﬂammatory condition (infections, trauma, etc) as
well as those with excessive alcohol intake and unusual di-
etary habits were also excluded from the study. According to
ATP III criteria, the metabolic syndrome was diagnosed in
the presence of any three of the following: waist circumfer-
ence > 102cm in men and > 88cm in women, triglyceride
≥ 150mg/dL (1.7mmol/L), HDL cholesterol < 40mg/dL
(1.0mmol/L) in men and < 50mg/dL (1.3mmol/L) in
women, blood pressure ≥ 130/85mmHg, or fasting glucose
≥ 110mg/dL (6.1mmol/L) [17].
BloodbiochemistryandHOMAtestofsubjects
Blood samples were obtained in the morning at 0800 after
a 12-hour overnight fast. Blood specimens were centrifuged
and the plasma was immediately frozen and stored at −20◦C
for analysis. Plasma values of free fatty acids, glucose, in-
sulin, LDL, HDL, hsCRP (high sensitive C-reactive protein),
triglyceride, total cholesterol, cytokines (TNF-α,I L - 1 α,I L -
1β, IL-6) were measured from all subjects. Height, weight,
and waist circumference (cm) were measured and BMI as
well as HOMA index was calculated. Free fatty acids were
measured at the University of Atat¨ urk (Erzurum, Turkey)
and the University of Yeditepe (Istanbul, Turkey) by collab-
orating with Dr Fikrettin S ¸ahin by gas chromatography us-
ing Sherlock microbial identiﬁcation system (MIS) software
(Microbial ID, Newark, Del, USA) with a database of FAME
proﬁles for eukaryocyte as described [18].
Plasma glucose levels were measured by glucose oxidase
method using a commercial kit (IL Test TM Glucose 182508-
40 (Instrumentation Laboratory, Italy)), triglyceride levels
were measured by enzymatic method using a commercial kit
(IL Test TM Triglyceride 182556-40 (Instrumentation Lab-
oratory, Italy)), total cholesterol was measured by bichro-
matic analysis using a commercial kit (IL Test TM Choles-
terol 182505-40 (Instrumentation Laboratory, Italy)), HDL
cholesterol was measured using a commercial kit (IL Test
TM HDL Cholesterol 182551-40 (Instrumentation Labora-
tory, Italy)) at an autoanalyzer (IIab 900/1800 Test (USA)) in
the Department of Biochemistry of the Cumhuriyet Univer-
sity Hospital. hsCRP was measured by ELISA (BioCheck Inc,
USA). IR was estimated by calculating homeostasis model
assessment (HOMA-IR) index (fasting serum insulin (μU/
mL)multipliedbyfastingplasmaglucose(mmol/L),thendi-
vided to 22.5) [19]. Serum insulin concentrations were mea-
sured at the Department of Nuclear Medicine, University
of Cumhuriyet, by immunoassay method using a commer-
cial kit (Diagnostic Products Corporation, USA). Sensitivity
was 2.0uIU/mL. Cytokines were measured by using ELISA
(BioSource, USA).
Wholebloodcytokineresponsesto
beta-hydroxyfattyacids
β-hydroxy myristic acid and β-hydroxy lauric acid were pur-
chased (Sigma-Aldrich, Germany), dissolved in 95% ethanol
(10mg/mL as stock solution), and incubated with whole
blood as described [20]. Brieﬂy, heparinized blood freshly
taken from healthy volunteers (n = 10) was diluted ﬁve-
fold with RPMI 1640 (Sigma-Aldrich, Germany) contain-
ing 2.5IU heparin (Vem, Turkey), 100IU penicillin (IE Ula-
gay, Turkey), and 100μg streptomycin (IE Ulagay, Turkey)
per mL. One milliliter of blood samples was used. After
addition of β-hydroxy myristic acid or β-hydroxy lauric
acid as 100ng/mL (0.5μM), 1μg/mL (5μM), and 10μg/mL
(50μM), the samples were incubated in polypropylene vials
in the presence of 5% CO2 at 37◦C for 0, 1, 2, 4, 8, and
24 hours. Ethanol (95%) was added to control vials as
0.0095μL/mL, 0.095μL/mL, and 0.95μL/mL, respectively.
Then, after shaking, the cells were pelleted by centrifugation
(400xg, 2min) and the cell-free supernatants were stored at
−80◦C for cytokine measurements. Cytokines (TNF-α,I L -
1α,I L - 1 β, IL-6) were measured by ELISA as described by
manufacturer (BioSource, Germany).
Statistics
Data were analyzed by unpaired t test. Results are expressed
as the mean ±SEM; P<. 05 was considered statistically sig-
niﬁcant.
RESULTS
The results of pilot experiments have shown that the
amounts of TNF-α,I L - 1 α,a n dI L - 1 β were not at detectable
level at all concentrations and incubation times for both
β-hydroxy myristic acid and β-hydroxy lauric acid. On the
other hand, IL-6 reached detectable levels at 24-hour incu-
bation with β-hydroxy lauric acid but not with β-hydroxy
myristic acid and the experiments were carried out by in-
cubation of 1mL whole blood with 100ng and 10μgo fβ-
hydroxy lauric acid for 24 hours (n = 10). Amount of IL-
6 released displayed diﬀerent proﬁle (Table 1). At 100ng, 5
o u to f1 0s u b j e c t sh a dh i g h e r ,4o u to f1 0h a dl o w e r ,a n d1
out of 10 had equal amount of IL-6 released compared to
vehicle control (537.5 ± 249.5 versus 494.5 ± 229.2pg/mL,
P = .46). At 10μg, the diﬀerence was signiﬁcant and 7 out
of 10 had higher and the rest 3 had almost equal amount of
IL-6 released compared to vehicle control (533.9±218.1v e r -
sus 438,3±219.6pg/mL,P = .019). 9 out of 10 subjects haveA. S. Soydan et al 3
Table 1: Amounts of IL-6 released from whole blood obtained from healthy men following incubation with 100ng or 10μgo fβ-hydroxy
lauric acid for 24 hours (n = 10, V; vehicle). Results were expressed as pg/mL (compared to vehicle, NS; not signiﬁcant).
Subjects means ±SEM P
12 3 4 56 7891 0
100ng 500 131 106 478 2115 31 56 19 67 1872 537.5 ±249.5 NS
V1 119 81 52 385 1837 52 274 130 141 1874 494.5 ±229.2
10μg 22 104 54 652 1811 92 370 256 200 1778 533.9 ±218.1 <. 05
V2 7 104 69 452 1663 23 107 37 119 1802 438.3 ±219.6
Table 2: Anthropometric and biochemical variables of patients with metabolic syndrome, RA, and cancer. Data were presented as means ±
SEM (compared to control, ∗P<. 001, ∗∗P<. 01, §P<. 05).
Control Metabolic syndrome Cancer RA
N 23 26 13 15
Age (y) 43.5 ±2.34 5 .11 ±2.05 7 .6 ±4.3∗∗ 53.9 ±2.4∗∗
Sex (m/f) 6/17 7/19 7/6 4/11
BMI (kg/m2) 29.5 ±1.13 5 .5 ±1.3∗ 22.2 ±1.2∗ 28.9 ±1.3
Waist circumference (cm) 91.8 ±3.6 105.5 ±2.7∗∗ 90.4 ±2.99 5 .9 ±3.2
Fasting glucose (mg/dL) 88.2 ±2.39 6 .0 ±3.2 114.3 ±16.1§ 89.9 ±5.0
HOMA-IR 2.3 ±0.35 .7 ±1.2∗∗ 2.8 ±0.83 .0 ±0.7
hsCRP (mg/L) 6.0 ±1.19 .0 ±0.9§ 20.7 ±2.3∗ 14.3 ±2.1∗∗
HDL (mg/dL) 37.0 ±1.74 4 .6 ±2.5§ 31.2 ±3.35 3 .9 ±4.8∗∗
LDL (mg/dL) 103.1 ±10.3 116.6 ±7.88 4 .4 ±8.6 107.2 ±8.6
Triglyceride (mg/dL) 135.2 ±12.4 195.3 ±19.3§ 161.2 ±35.8 124.4 ±11.3
Total cholesterol (mg/dL) 170.8 ±9.2 200.5 ±9.5 147.7 ±13.6 183.7 ±10.5
TNF-α(pg/mL) 1477.3 ±240.1 1431.8 ±114.4 1467.7 ±136.3 1552.1 ±215.1
IL-6 (pg/mL) 27.7 ±4.42 1 .5 ±4.26 3 .5 ±8.6∗ 41.1 ±11.7
Weight (kg) 77.2 ±2.49 0 .4 ±2.9∗∗ 63.2 ±3.6∗∗ 73.7 ±3.1
higheramountofIL-6releasedateither100ngor10μgc om-
pared to vehicle control. Only 1 subject had at almost equal
amount of IL-6 released at both dose.
Anthropometric and biochemical variables in patients
w e r ep r e s e n t e di nT a b l e s2 and 3. BMI, waist circumfer-
ence, HOMA index, the amounts of hsCRP, HDL, triglyc-
erides, and weight were signiﬁcantly higher in patients with
metabolic syndrome compared to control. Age, fasting glu-
cose, hsCRP, and IL-6 concentrations were signiﬁcantly
higher in cancer patients compared to control. On the other
hand, BMI and weight were signiﬁcantly lower in cancer
patients. Age, hsCRP, and HDL concentration were signiﬁ-
cantly higher in RA patients compared to control. PCOS pa-
tients were compared with only female controls (Table 3).
Age, BMI, waist circumference, the concentration of IL-6,
and weight were signiﬁcantly lower in patients with PCOS
compared to control. The amounts of major free fatty acids,
as a % of total amount, were shown in Tables 4 and 5.W e
were not able to detect either β-hydroxy myristic acid or β-
hydroxylauricacidinoursubjects.PCOSpatientswerecom-
pared with only female controls (Table 5).
DISCUSSION
The relationship between dietary fatty acids and inﬂamma-
tion has been shown by in vivo and in vitro studies [21–24].
Saturated, particularly lauric, fatty acids seem to induce cy-
tokine production as well as expression of cyclooxygenase-2
in vitro [25]. In addition, Weatherill et al [26]h a v ef o u n d
that lauric acid upregulated the expression of cytokines (IL-
12p70 and IL-6) in bone marrow-derived dendritic cells. On
the other hand, eicosapentaenoic acid (20 : 5, n − 3) and
docosahexaenoic acid (22 : 6, n − 3) inhibited in vitro pro-
duction of IL-6 by human endothelial cells [27]. Supplemen-
tation of a diet with EPA and DHA also reduced cytokine
p r o d u c t i o ni nh u m a ni nv i v o[ 22, 23]. Prospective studies
indicate that increased IL-6 and CRP concentrations as well
as fatty acid composition are associated with IR and cardio-
vascular events [28–30].
This study presents a novel approach to understand
the relationships between fatty acids, chronic inﬂammation,
and IR. As far as we know, this is the ﬁrst study to in-
vestigate the role of β-hydroxy fatty acids on inﬂamma-
t i o na n dI Rb o t hi nv i v oa n di nv i t r o .W ef o u n dt h a tβ-
hydroxy lauric acid increased the amount of IL-6 released,
proinﬂammatory cytokine, by human blood cells in vitro.
At high concentration (10μg/mL), the eﬀect of β-hydroxy
lauric acid reached statistical signiﬁcance (P<. 05). β-
hydroxy myristic acid did not increased the amount of IL-
6 released by peripheral human blood cells in vitro. Since
there is a strong association between mediators of inﬂam-
mation (such as IL-6) and IR, it was important to measure4 Mediators of Inﬂammation
Table 3: Anthropometric and biochemical variables of patients with PCOS. Data were presented as means ± SEM (compared to control,
∗P<. 001, ∗∗P<. 01, §P<. 05).
Control PCOS
N 17 24
Age (y) 44.5 ±2.92 4 .7 ±1.2∗
BMI (kg/m2) 31.3 ±4.72 5 .9 ±1.3∗∗
Waist circumference (cm) 92.8 ±4.48 2 .0 ±3.0§
Fasting glucose (mg/dL) 90.6 ±2.38 5 .8 ±1.9
HOMA-IR 2.4 ±0.42 .0 ±0.3
hsCRP (mg/L) 6.1 ±1.26 .0 ±1.0
HDL (mg/dL) 38.6 ±2.24 2 .6 ±2.7
LDL (mg/dL) 96.9 ±10.1 111.5 ±9.1
Triglyceride (mg/dL) 140.8 ±15.9 140.9 ±13.1
Total cholesterol (mg/dL) 169.3 ±10.2 181.0 ±9.7
TNF-α(pg/mL) 1566.2 ±305.3 1334.0 ±125.1
IL-6 (pg/mL) 24.2 ±5.45 .2 ±1.8∗∗
Weight (kg) 77.5 ±3.06 6 .8 ±3.4§
Table 4: The amounts of major free fatty acids (FFAs) as % of total amount in plasma of patients with metabolic syndrome, RA, and cancer.
R e s u l t sw e r ee x p r e s s e da sm e a n s± SEM (compared to control, ∗P<. 001, ∗∗P<. 05).
FFAs Control (n = 23) Metabolic syndrome (n = 26) Cancer (n = 13) RA (n = 15)
14 : 0 1.99 ±0.27 2.02 ±0.14 1.41 ±0.29 1.82 ±0.20
16 : 0 26.96 ±0.64 26.95 ±0.56 25.73 ±0.75 29.14 ±0.83∗∗
16 : 1 (n −7) 4.20 ±0.51 5.21 ±0.28 4.48 ±0.56 4.06 ±0.43
18 : 0 7.09 ±0.35 5.76 ±0.42∗∗ 4.62 ±0.18∗ 8.04 ±0.50
18 : 1 (n −9) 19.43 ±0.48 19.56 ±0.60 19.25 ±0.81 21.57 ±1.00∗∗
18 : 2 (n −6) 35.06 ±1.44 32.72 ±0.83 36.54 ±1.93 30.73 ±1.64
20 : 4 (n −6) 4.72 ±0.42 5.97 ±0.41∗∗ 7.58 ±0.62∗ 4.40 ±0.57
20 : 3 (n −6) 2.19 ±0.21 1.95 ±0.01 1.76 ±0.28 2.53 ±0.42
Table 5: The amounts of major free fatty acids (FFAs) as % of total
amount in plasma of patients with PCOS. Results were expressed as
means ± SEM (compared to control, ∗P<. 001, ∗∗P<. 01, §P<
.05).
FFAs Control (n = 17) PCOS (n = 24)
14 : 0 1.64 ±0.09 2.40 ±0.31§
16 : 0 27.19 ±0.90 23.90 ±0.50∗∗
16 : 1 (n −7) 4.02 ±0.43 3.69 ±0.29
18 : 0 7.30 ±0.42 4.86 ±0.19∗
18 : 1 (n −9) 19.47 ±0.64 16.50 ±0.52∗
18 : 2 (n −6) 35.88 ±1.88 39.45 ±1.21
20 : 4 (n −6) 4.98 ±0.50 7.63 ±0.27∗
20 : 3 (n −6) 2.05 ±0.24 2.00 ±0.01
β-hydroxy lauric acid in plasma of patients with chronic
inﬂammatory diseases associated with IR. HOMA-IR in-
dex was higher in cancer, RA, and metabolic syndrome pa-
tients, but not in PCOS patients. However, we did not de-
tect free β-hydroxy lauric acid in plasma. This could be ex-
plained in two ways. The ﬁrst one is that there was no free
β-hydroxy lauric acid in samples. The second one is that the
amount was not at detectable range. The method we used
allowed us to measure free fatty acids as only a percent in
total.
A major component of LDL is phosphatidylcholine (PC)
and 40% of LDL-PC can be converted to lyso-PC by phos-
pholipase A2 activity during oxidative modiﬁcation [31].
Lyso-PC stimulated human monocytes to produce IL-1β,o n
bothproteinandmRNAlevels,inadoseandtime-dependent
manner [32]. The acyl chain length and saturation of lyso-
PC were important for this stimulating eﬀect. There were
no eﬀects when the acyl chain of lyso-PC was less than
C16 and lyso-PC 18 : 1 had much less eﬀect than lyso-PC
18 : 0. Although we did not determine free β-hydroxy lau-
ric acid in plasma of patients with chronic inﬂammation
associated with IR, it stimulated the release of IL-6 in cul-
ture conditions. Therefore, further studies may be required
to investigate the existence of β-hydroxy lauric acid in the
structure of complex lipids such as phospholipids, lipopro-
teins, and so forth. The results of those studies might be
helpful to understand the involvement of fatty acids as an
endogenous molecule in sterile chronic inﬂammation and
IR.A. S. Soydan et al 5
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